Now, CXCR2 (the receptor for CXCL1 secreted by tumor cells), CCR4 (CCL17, the ligand for CCR4), and others have been modified to enhance T-cell trafficking to the tumor site (90–92). This evidence concerns the gene CCL17 and neoplasm.